RAC - Charts & Price Action, page-14352

Nothing for retail to latch onto? There's always the four relapsed and/or refractory patients taken to stem cell transplant that everyone seems happy to forget, or only half remember.

It's 30 months since we got the FTO gift and Race has failed to get Zantrene into one patient in a Race led trial - and it's not because they were being careful in trial design. It's now 12
months since we applied for ethics approval, so the trial design was done ages ago. The ethics approval should have been approached so that it happened faster and we should have designed the trial to get to patient dosing faster. This week they are blaming doctors for not putting up their patients for EMD scans and making claims that suggest they think that the doctors are at fault. Dr T knows how oncologists behave and designing a trial in a regional hospital, in a sub-type of a rare disease, where the oncologists aren't going to stream their patients into the trial is the fault of the Race team.

Time for the Race team to stop acting like they can do no wrong and acting like they're smarter than everyone else.

Take responsibility for progress and take responsibility for getting the compelling, understandable message out there.

We're sitting on an opportunity where the addressable market is dozens of billions in revenue each year in each of multiple fields. The $2-odd share price at this time is a joke